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ARTICLE
Clarifying ethical responsibilities in pediatric biobanking
Merle Spriggsa and Craig L. Fryb
aChildren’s Bioethics Centre, Centre for Health Equity, School of Population Health, University of Melbourne and Hearing, Language and Literacy,
Population Health, Murdoch Childrens Research Institute; bCulture and Values in Health, Centre for Cultural Diversity and Wellbeing, Victoria University
ABSTRACT
Background: The creation of biobanks for storage of human specimens and use in health and medical
research is expanding globally. Biobanks hold signiﬁcant potential to facilitate such research. However,
important ethical questions arise, particularly in the pediatric setting, in relation to consent, future use,
and the balance of beneﬁts against potential harms. To date, these ethical issues have been
undertheorized and underresearched in the biobanks domain. The aim of this study was to examine
stakeholder attitudes regarding the ethical responsibilities of researchers, biobank custodians, Human
Research Ethics Committees (HRECs), research institutions, and parents. Methods: A qualitative study
using semistructured interviews with a purposive sample of key informants (n D 14) with relevant
expertise was conducted. Participants were interviewed about their pediatric biobank experiences, the
main ethical issues observed as an HREC member, researcher, or custodian, and future needs. Results:
Participants expressed concerns about consent processes in the biobanking context, including issues
regarding the provision of information, level of understanding, voluntariness, and the point at which
children have a role or can consent for themselves. Other major issues raised were biobank quality
management, the return of results, and the idea of human tissue as a scarce precious resource. Key
informants also highlighted uncertainties about the custodianship of biobank samples and reasonable
limits on the custodian’s role. Conclusions: Pediatric biobanks are a valuable resource, presenting unique
opportunities to advance children’s health and well-being. Properly run pediatric biobanks entail
responsibilities for institutes, custodians, researchers, and research ethics committees. We discuss ethical
implications for pediatric biobank policy and practices, as well as future information needs in light of the
study ﬁndings.
KEYWORDS
ethics; biobank; pediatric
biobank; informed consent;
parental consent
What is a biobank?
Biobanks have some deﬁning features, but there is no consen-
sus on what is a “biobank” (Gibbons et al. 2007; National
Health and Medical Research Council [NHMRC] 2010). Our
working deﬁnition of a biobank includes large-scale or smaller
scale population collections of samples, and disease-speciﬁc
collections. Samples within these collections are generally
linked to other personal and health information, but some are
not. Our deﬁnition includes research collections and nonre-
search collections. Nonresearch collections include those estab-
lished for diagnostic, therapeutic, treatment, quality assurance,
or public health purposes or as teaching materials. Samples
include blood, saliva, cheek scrapes, cord blood, feces, biopsy
material, placenta, urine, bronchial lavage, images, and pediat-
ric tumor cells.
Project rationale
Collecting and storing tissue and information from children
provides a resource and unique opportunities to learn more
about children’s health and well-being. Beneﬁts may be for chil-
dren in general or children with a speciﬁc disease. The success
of biobanks depends on the support of the community and
their willingness to contribute to biobanks (Gurwitz et al. 2009;
NHMRC 2010). It is crucial, therefore, that we identify ethical
issues and clarify ethical responsibilities around children and
biobanks. Public trust is essential for the collection of tissue
and data from children to proceed. It is recognized that scan-
dals such as the unauthorized retention of children’s organs by
researchers in the United Kingdom have undermined public
trust (Williams and Schroeder 2004; Williamson and Smith
2004), and adversely affected the donation of tissue for legiti-
mate research—even research not directly linked to the scandal
(Seal et al. 2005).
Consent is the most frequently discussed ethical issue in
relation to biobanks generally (Budimir et al. 2011). While
there is debate about whether consent is needed at all in bio-
bank research when consideration is given to the “public inter-
est” or the “common good” (Forsberg, Hansson, and Eriksson
2011), there are also persuasive critiques of the uncritical think-
ing that sometimes underlies the idea of the “common good.”
For instance, critics challenge “unquestioned assumptions”
such as the idea that seeking consent comes at the cost of the
public interest and that dispensing with or relaxing consent
requirements serves the “common good” (Arnason 2011, 563;
Rommetveit 2011, 585).
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Most of the discussion around consent and biobanks focuses
on the consent form and the type of consent that is required
(Budimir et al. 2011). Types of consent include consent limited
to a speciﬁc project; consent for future research related to or in
the same general area for which the original consent was given;
and consent that is for any future research purpose (NHMRC
2007; Organization for Economic Cooperation and Develop-
ment [OECD] 2006; 2009).
Consent is also identiﬁed as “the most widely discussed
issue” in a review of the ethics literature and guidelines about
children and biobanks (Hens, Levesque, and Dierickx 2011,
406). However, where children are involved, the issues are
more complex. Children need someone else to consent on their
behalf (parent or guardian), making the “value” of the consent
“fundamentally different” (Hens, Levesque, and Dierickx 2011,
404). According to Hens, Levesque, and Dierickx, the literature
and the guidelines are “fairly unanimous” about who should
consent. The “need for and the validity of parental consent” is
not questioned in the literature, nor “the right of a child to give
his or her own opinion on the matter” (Hens, Levesque, and
Dierickx 2011, 407). But there is no consensus on whether
parents have the right to consent to future unspeciﬁed research
on the stored tissue samples of their children, and there is
“uncertainty” about the age at which children can be involved
in decisions about participation (Hens, Levesque, and Dierickx
2011, 407). There is “some agreement” that “children should be
able to renew their consent when they reach the age of compe-
tence” (Hens, Levesque, and Dierickx 2011, 407).
In the literature about pediatric biobanks, one prominent
argument is that researchers can collect DNA samples and data
from children but that they should wait until children are old
enough to give their own consent before researchers can share
the children’s samples with other researchers. The underlying
idea here is that while children are vulnerable in the sense that
they need others to decide on their behalf, their “vulnerability
is temporary” (Gurwitz et al. 2009, 818). Others strongly
oppose the view that sharing children’s samples should wait
until they can consent for themselves—they claim that the wait
is “too long” (Brothers and Clayton 2009, 798).
The question of whether to return individual results from
biobank-based research is an issue that ﬁgures prominently in
the literature. Returning results can be a beneﬁt but it can also
be a harm (Wolf et al. 2012), and it raises different issues where
children are involved. We can ask adults whether they want to
receive information that may emerge about their health, and
they can elect to be informed or they can choose not to know.
Where children are concerned, it is not clear that parents
should be provided all information about their child that
becomes available (e.g., the child’s genetic makeup) or that
parents should have the right to say they do not want to receive
results that could contain information that is of beneﬁt to their
child (Hens, Levesque, and Dierickx 2011).
A considerable part of the literature on biobanks is made up
of stakeholder opinions, mostly participant attitudes (Budimir
et al. 2011). While participant attitudes have an important role,
others suggest that “opinion sampling” is not an adequate sub-
stitute for informed discussion and debate (Williams and
Schroeder 2004, 271). To illustrate, studies show that parents
agree to have their children’s samples stored in pediatric
biobanks even though they do not “fully” understand risks,
conﬁdentiality, the aims of the research, and the experimental
nature of the research (Budimir al. 2011, 272; Klima et al.
2014). What is more, there is a lack of research demonstrating
effective processes for gaining valid consent in pediatric bio-
banks (Klima et al. 2014).
In their content analysis of the literature on biobanks, Budi-
mir et al. (2011) identify issues of importance that have received
little attention. These include commercialization, the “role of
ethics boards” as opposed to the “opinions” of ethics boards,
and international collaboration or “data exchange” (267, 271).
Others argue that in addition to the central ethical issue of
consent, there are other important issues regarding the ethical
acceptability of biobanking. For instance, it has been argued
that custodians of large-scale biobanks should actively take on
the following responsibilities (Williams and Schroeder 2004):
 Encourage public debate about the use of tissue and data.
 Sponsor research that “reﬂects publicly agreed priorities
and provides public beneﬁt” (89).
 Guard against problematic uses of tissue and data.
 Provide “regular public reporting” on “actual beneﬁts
obtained”—not only “the speculated beneﬁts” (99).
While some of the matters mentioned here are not speciﬁc
to children, they are equally relevant. We argue they are more
pressing and there is more at stake when biobanks include chil-
dren—children who need other people to consent on their
behalf. As well as the potential gains for children’s health, chil-
dren may suffer the effects for longer if anything goes wrong.
The ethical responsibilities that are generated for researchers,
biobank custodians, Human Research Ethics Committees
(HRECs), research institutions, and parents are areas that are
underresearched in the area of pediatric biobanking.
Capron et al. (2009) note the “lack of empirical data” on
“speciﬁc ethical concerns” in the area of genetic databases and
biobanks and have sought the views of international experts
(101). Nevertheless, their research does not address or refer to
the collection of tissue and data from children or pediatric bio-
banks. We believe that issues affecting children and ethical
responsibilities in the context of pediatric research biobanks
warrant special consideration.
The central aims of this study were to identify the main ethi-
cal issues and clarify the ethical responsibilities of researchers,
biobank custodians, HRECs, research institutions, and parents
that are generated by the collection, storage, and use of child-
ren’s biological samples and data. This is the ﬁrst such study to
examine these issues in the Australian context.
Methods
Sample
As the goal of this study was to identify ethical issues and clarify
responsibilities in pediatric biobanking, we sought the views of
experts in the ﬁeld. We employed a purposive sampling approach
to identify and recruit a diverse range of expert informants (Sar-
antakos 1998). We compiled an initial list of twelve potential
expert informants through multiple sources, including keyword
searches of websites and word-of-mouth referrals.
Our aim was to recruit people with current and direct expe-
rience in pediatric biobanking, such as biobank custodians;
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researchers who collect, store, or use children’s biological sam-
ples and data; people who review a signiﬁcant number of bio-
bank research studies involving children’s samples and data;
and others with relevant expertise, such as members of biobank
advisory boards and informants with education and ethics
expertise in pediatric biobanking and research.
Recruitment and interview
Initial contact with identiﬁed experts was made via an e-mail let-
ter providing an overview of the study aims and methods, and
an invitation to participate in a semistructured interview. Of 12
potential participants whom we emailed directly, nine agreed to
take part in the study.We also sent an e-mail invitation to partic-
ipate in the study via secretariats of selected HRECs and an elec-
tronic bulletin at a Children’s Research Institute, which resulted
in a further ﬁve people recruited to the study.
Semistructured interviews were conducted with 14 partici-
pants (six female, eight male) selected for their current expertise
relevant to pediatric biobanking. Participants had multiple roles
and positions (current and past) and training in ﬁelds that gave
additional weight and relevance to their contributions. Partici-
pants were made up of researchers and custodians (some with
their own lab or who were in charge of lab services); those who
review biobank research involving children’s data and samples;
those developing guidelines and policy for pediatric biobanks;
those involved with research governance; and a member of an
international biobank scientiﬁc advisory board. Six of the 14
participants have been involved in setting up biobanks and/or
biobanking processes. Eight participants have signiﬁcant cur-
rent or past roles with research ethics committees and at least
half of these are also researchers or custodians. At least four par-
ticipants have formal ethics qualiﬁcations or training.
Participants have experience with the following biobanks and
biobank research: disease-speciﬁc biobanks; tumor biobanks;
large population biobanks; nonresearch collections (e.g., for
diagnostic purposes); population research; longitudinal cohort
studies (birth, child, and adolescent); international consortia of
child and birth cohort studies; twin studies; studies involving
data linkage; genetic research; and establishing cell lines.
The method of data collection was semistructured inter-
views. We asked participants about their involvement with
pediatric biobanks, what they see as the main ethical issues,
and things they have found to be problematic in their role on a
HREC or as a researcher or custodian. Participants were also
asked about their attitudes on future needs and issues they
would like to see investigated further.1 Author MS conducted
individual semistructured interviews in person or by telephone
and took detailed notes during the interviews. Permission was
sought to recontact informants for clariﬁcation if necessary.
Data analysis
Interviews ranged from between 25 to 65 minutes with an aver-
age of 40 minutes. Data were analyzed at two levels: (i) induc-
tive (or interpretative) content analysis to clarify content
categories (organizing relevant data around interview questions
where appropriate), and (ii) thematic analysis to identify main
issues and themes (Manning and Cullum-Swan 1994; Strauss
and Corbin 1990). During the analysis phase, the study team
held a number of meetings to discuss and agree on the method
of analyses. Rigor of analysis is evidenced by our inclusion of
examples from the data demonstrating the context of themes
or content categories identiﬁed (Hansen 2006).
The ﬁndings are in accordance with COREQ criteria for
qualitative research (Tong, Sainsbury, and Craig 2007). Find-
ings are arranged according to the four main ethical issues
identiﬁed by the expert informants. See Figure 1 for a summary
of the main ﬁndings.
Ethical approval
Study ethics approval was obtained from the Royal Children’s
Hospital, Human Research Ethics Committee.
Results
Consent
The most commonly discussed ethical issue was consent. Key
elements of informed consent were the basis of many
concerns—crucial matters such as the provision of information,
level of understanding, voluntariness, and the point at which
children have a role or can consent for themselves.
Validity of consent was a major concern for some inform-
ants, and this concern had a number of sources:
 What information and how much information should be
disclosed so that consent is informed? (Experts 1, 9)
 Information may be unavailable, unknowable, or uncer-
tain because “you don’t know the speciﬁcs of the
research” at the time tissue is collected. (Expert 5)
 People may not be getting relevant information. Accord-
ing to one informant, information on how insurance
could be impacted may be available, but researchers are
not explaining it. (Experts 13, 14)
 The person providing information for consent may have
conﬂicting interests. For instance, researchers often say
“it’s completely anonymized, but it’s re-identiﬁable.… In
order to encourage participation, they don’t accurately
inform.” (Expert 13)
 There may be difﬁculties in understanding information.
Potential participants may not really understand where
the data are going and what they are consenting to.
(Expert 4,7)
The function and the value of consent in pediatric biobank-
ing came under scrutiny (with a focus on the role of the child
and the parent):
Is it OK for parents to consent? (Expert 8)
At what point should the child have a role and at which age?
(Expert 4)
At some age … you need to get independent consent from
the child. (Expert 8)
Some informants worried about the voluntariness of children’s
participation due to possible pressure from parents—even
though the children may agree to participate (Experts 14, 7).1 A copy of the interview questions is available from the authors upon request.
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There was also concern that when children reach an age where
they can consent for themselves and parental consent no longer
applies, they may not know that their samples have been stored:
“Most children at 18 wouldn’t know about samples” and there
is “no onus to inform people” (Expert 2).
Waivers of consent were an area of difﬁculty for researchers
and HRECs because of the requirement that a review body
must be satisﬁed that “it is impracticable to obtain consent”
(NHMRC 2007, 21). This requirement was thought to be get-
ting “more stringent” and “more and more” researchers are
being told they have to try to get consent (Expert 2). Another
view was that “sometimes” it is just that researchers “can’t be
bothered,” not that consent is “impracticable” (Expert 14).
Consent ﬁgured signiﬁcantly in the things that informants
nominated for further investigation. They wanted to know the
type of consent that is appropriate in pediatric biobanking (e.g.,
speciﬁc, extended or unspeciﬁed); whether research can con-
tinue without young people’s reconsent; and where consent or
reconsent is required, what information and options should be
provided (Experts 3, 4, 5, 6, 9, 13, 14). A member of an ethics
committee spoke about the need for clear and accurate infor-
mation on biobanking and behavioral genetics research:
“Researchers can be a bit cavalier at times … tend to get irri-
tated when asked about the division between genetic testing
and genetic studies” (Expert 13).
Quality management
Quality management emerged as a major theme in this research.
It was referred to in some form or other by almost all of the expert
informants (Experts 2, 3, 4, 5, 6, 7, 8, 10, 11, 13). The quality man-
agement issues they talked about included ideas such as having
and maintaining proper processes, living up to promises, and
being trustworthy—“Sticking to what you’ve told the patient you
will do” (Expert 3), and what at least one informant referred to as
“properly run” biobanks (Expert 8).
According to this informant:
It’s not so much about informed consent, but biobanks living up to
the promises they make in relation to protecting privacy and
Figure 1. Summary of main ﬁndings.
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advancing health. And, if they can’t do something, don’t suggest
they can—don’t promise. (Expert 8)
This informant went so far as to say that the “main issue” is
“properly run biobanks and reporting back ﬁndings without
causing harm… it’s not a consent thing. Can’t just rely on con-
sent” (Expert 8).
Another suggested that “individuals’ welfare could be
affected” if, for instance, conﬁdentiality is not protected, or
there is access to materials by those who should not have it,
loss of biospecimens or identifying information, inaccurate
results, and giving wrong information (Expert 11).
Sustainability is a related concern:
What happens in 20 years? (Expert13)
What if the research institute ceases to exist or is taken over
by someone else? (Expert 8)
Does the researcher’s responsibility end when the money
runs out? (Expert 4)
These are important questions, and expert informants are rais-
ing them because they do not have answers. These questions
are clearly not receiving the attention they deserve.
Tissue as a scarce precious resource
Tissue as a scarce precious resource was a signiﬁcant issue for
some informants: “Such a precious resource is often irreplace-
able” (Expert 10). There was concern about whom the samples
should be given to: “Brain tumors, if 100 samples, there is
only so much you can do with it. Which research should get
the sample?” (Expert 1). In addition to which research gets the
sample, there is also the matter of who should get access to
samples for collection and storage. One informant described
“competition from multiple groups wanting to access the sam-
ples from the same population sample” as a signiﬁcant chal-
lenge: “six groups wanting to access blood from healthy
children having minor surgery. To date it has been cordial—
one will have it one day and another the next” (Expert 5).
In terms of this scarce precious resource, there was a lack of
clarity amongst the expert informants about the role and respon-
sibilities of research ethics committees and custodians: “Because
it is an important resource, you have to be careful about who they
are released to … the project has to be valid, worthwhile to get
maximum beneﬁt from the resource” (Expert 10).
Return of results
The question of whether to return individual results was
another signiﬁcant issue (Experts 4, 8,12, 13). One informant
asked, “What if we identify information that is important for
their health … if you ﬁnd information inadvertently?” (Expert
12). Another postulated that “feedback of results to individuals
is a possible harm. First stipulation is that there are really clear
plans about whether information will be fed back and if it will
be, how it will be done” (Expert 8).
Discussion
This is the ﬁrst study to examine stakeholder attitudes about
the key ethical issues that arise in the Australian pediatric
biobanking context in relation to consent, future use, and the
balance of beneﬁts against potential harms. The expert key
informant participants of this study expressed concerns about
current consent processes in the biobanking context, including
issues such as the provision of information, level of understand-
ing, voluntariness, and the point at which children have a role
or can consent for themselves. Other major issues raised were
related to biobank quality management, the return of results,
and the idea of human tissue as a scarce precious resource. Key
informants also highlighted uncertainties about the custodian-
ship of biobank samples and the role of the custodian.
In what follows, we discuss how the major issues identiﬁed
reﬂect what is at stake where children are concerned and how
that translates into responsibilities for pediatric biobanks. To
demonstrate what is important about these ethical issues and
the ethical responsibilities they generate, we again draw atten-
tion to what is different or special about pediatric biobanks—
namely, the collection, storage, and research use of biological
samples and data from children.
The ﬁndings in this study reﬂect what it is that makes con-
sent problematic when children are involved. Because of their
vulnerability (limited cognitive capacity), children need others
(proxy decision makers, generally parents) to look out for their
interests and to make decisions on their behalf—but that is not
a situation that lasts forever.
Added to that, consent by proxy is a challenging concept in
the research context. It raises the question of whether one per-
son can volunteer another person. Furthermore, in the context
of pediatric biobanks, the proxy decision maker may be making
an irreversible decision, forsaking the child’s ability to with-
draw from the research. Withdrawal from research is effectively
not possible once samples and data are shared with other
researchers (e.g., via a research collaboration).
While it is accepted that parents make irreversible decisions
for their children that are not in their strict best interests,
according to some, this is a decision that “could just as well” be
a reversible decision “at the point when the child reaches deci-
sional competence” (Gurwitz et al. 2009; Holm 2005, 21). Some
go as far as suggesting that “there can be no reason, apart from
the convenience of the researchers, to renounce withdrawability
at the proxy consent stage” (Holm 2005, 2122). Considerable
importance is placed on children’s ability to renew their con-
sent when they reach the age of competence and their ability to
withdraw from research (Hens, Levesque, and Dierickx 2011;
Holm 2005). What this all boils down to in the pediatric con-
text is that parents need to understand exactly what they are
consenting to on behalf of their child. This also generates a
range of ethical responsibilities. See Figure 2 for a summary of
ethical responsibilities.
It can be taken as a given that it is the parents’ role and
responsibility to understand what is involved in pediatric bio-
banking before they give their consent. That includes details
about the potential beneﬁts, risks, and the implications of par-
ticipation. While full information is not a realistic goal, parents
do need information that makes a difference to whether they
want to enroll their child or not. That includes knowing
whether there is information that is not known, uncertain, or
unavailable. They also need information about contentious
issues and debates relating to speciﬁc types of research they are
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being asked to enroll their child into. They also need to know
how promises made by the biobank and researchers will be
upheld, particularly in the setting of international collabora-
tions between biobanks and researchers (Birmingham and
Doyle 2009).
A current issue relevant to consent is the data protection
reform that is underway in the European Union and the
accompanying concern about what it may mean for biobank
research. According to some, “broad consent” may no longer
be a “lawful option,” and a requirement for speciﬁc consent
will make research unworkable (Kay et al. 2015; Wellcome
Trust 2014). While there are international initiatives to ﬁnd a
set of principles to improve governance and interoperability
around the sharing of data and biospecimens (Mascalzoni
et al. 2014), there are others who complain that “huge lobby
groups are trying to massively inﬂuence the regulatory bodies”
and weaken data protection (Signatories 2013, 180).
A 2015 fact sheet issued by the European Commission
addressing the question of how the reforms will affect scientiﬁc
research states that scientiﬁc research “stands to beneﬁt from
the proposed data protection reform” (European Commission
2015, 5). Clearly, conﬂicting views currently exist. This high-
lights the need for further research and analysis of how data
protection reform may affect biobank research, in particular
Figure 2. Ethical responsibilities in pediatric biobanking research.
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pediatric biobanking research with its complex consent issues—
but that is beyond the scope of our study.
The responsibility to inform parents about the things that
matter to them (things that affect their willingness to take part
and enroll their child) belongs to researchers, and it is for
research ethics committees to ensure that researchers meet that
responsibility. Arguably, parents’ responsibility is greater when
consenting for a child than when consenting for themselves.
Studies show that many adult tissue donors give unspeciﬁed
consent for future research, and they are unconcerned about
detailed information (Lipworth et al. 2009). While that may be
acceptable for competent adults consenting for themselves, it is
not when they are consenting on behalf of a child.
When children need someone else to make decisions on
their behalf, they need someone who takes note of the details.
Details in addition to those already listed here include privacy
protections—whether information can be accessed by other
researchers (including researchers outside Australia), third par-
ties such as police or government departments, or even parents
(or children themselves when they are older) through freedom
of information laws. Parents also have the responsibility of ask-
ing questions about things they do not understand.
Although consent was the topic that received the greatest
amount of attention from expert informants in this study, not
all informants were saying that consent was the most important
thing. Nearly all talked about quality management issues or
what was sometimes referred to as “properly run biobanks.”
Quality management is not typically considered an ethical
issue, but in this context it is ethically very important. Parents
need to know what they are consenting to, and that crucially
depends on properly run biobanks.
Biobanks also need to be “properly run” in order to live up
to the promises on which consent is given. This is clearly artic-
ulated by one informant who claimed that “if the tissue is not
usable down the track, you have breached the ethical agreement
you had with the people you got consent from” (Expert 5).
Quality management also matters in terms of the risk/bene-
ﬁt calculation. If beneﬁts are unrealizable or undermined
because of poor procedures, risk of any level cannot be justi-
ﬁed—the risk is for nothing. The opportunity to advance child-
ren’s health is lost, and it will damage the public trust that is
essential for pediatric biobanks to function. Quality manage-
ment issues, therefore, take on a special importance in pediatric
biobanking research.
There is a growing international push to accept the sharing
of samples and data with other researchers as a necessary way
to optimize use and value (Mascalzoni et al. 2014). We hold
that sharing of samples and data is different for pediatric bio-
banks because of the issue of withdrawability. Voluntary partic-
ipation is a fundamental aspect of ethical research, and that
includes the ability to withdraw from research. Proper proce-
dures are needed for that to be possible, for example, proce-
dures and processes to identify and withdraw samples and
information. As noted earlier, some people argue that sharing
of samples with other researchers may need to wait (Gurwitz
et al. 2009). This is an area of intense debate that only occurs in
pediatric biobanking (Brothers and Clayton 2009; Gurwitz
et al. 2009; Holm 2005). While this is partly a consent issue, it
is also a quality issue.
Tissue as a scarce precious resource is also different in pediat-
ric biobanking in the sense that it involves “additional and
unique barriers” such as fewer investigators, fewer subjects, a
preponderance of rare illnesses, difﬁculties in sample collection
methods, and small tissue sample volumes (Brisson et al. 2012,
154)—and there is more at stake: more to gain and more to lose.
Pediatric tissues can be analyzed to tell us more about the ear-
lier prevention and treatment of high cost, high prevalence, high
burden conditions, or diseases where earlier intervention is pos-
sible because we are dealing with children. Because of the poten-
tial for early intervention and avoiding conditions/diseases
developing into chronic problems with high population preva-
lence, it is more important to get the decisions right around col-
lection and use of the scarce resource of children’s tissues.
Biobank advocates certainly argue this (Brisson et al. 2012).
The idea of tissue as a “scarce precious resource” raises ques-
tions about the release of samples and questions about who
should be deciding. For instance, is a well-designed study that
has ethics approval an adequate reason to give out a scarce pre-
cious resource like children’s brain tumor samples? Can the per-
son who collected the samples say “no”? Can the person who is
in charge of the samples say “no”? Could the HREC choose not
to approve the study even though it is well designed?
It is noteworthy that responses of experts in pediatric bio-
banking reveal a lack of agreement or at least uncertainty about
who is the custodian of biobank samples and about the role of
the custodian. Some think the custodian is the researcher, some
suggest it is the person in charge of the samples, and some sug-
gest that it is a role for the research ethics committee. It is pos-
sible that the causes of this uncertainty may be discipline
dependent. The scientiﬁc community tends to see the hands-on
manager as the custodian, while lawyers would regard the cus-
todian as the one with legal responsibility and control, usually
the institution that “owns” the biosamples.
Nevertheless, this is an area that needs clariﬁcation (and
harmonization for collaborative research) in biobank policy.
Key questions are: (i) Who should be the custodian? (ii) What
is the role of the custodian? (iii) What is the extent and what
are the limits of the custodian’s role?
Regardless of who the custodian is, there is a need for bio-
banks, research institutes, and HRECs to have policies and pro-
cedures about who can get access to samples and who should be
making the decisions on these matters. There is also a need for
policies and procedures to determine when, if ever, third parties
can access biobank data and samples, and when, if ever, and on
what criteria, a child’s results can be given to parents. As men-
tioned earlier, return of results has the potential to cause harm
and the issues are different where children are involved.
There remains one unallocated responsibility, that is, the
responsibility to inform children (who may not know that they
have samples stored in a biobank) when they are old enough to
give their own consent for research to continue. Most likely,
this is an oversight that will become outdated as new biobanks
and studies get set up.
Conclusion
Pediatric biobanks are a valuable resource, presenting unique
opportunities to advance children’s health and well-being.
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Consent of the parent and, where appropriate, consent of the
child, are very important, but they are not the only important
things. A key ﬁnding of this project is that quality management
has major ethical implications that affect consent, risk, and public
trust.
Pediatric biobanks (like any biobank) need to be properly
run to achieve anticipated beneﬁts. That means they need a
clear quality management program, and they need to live up to
the promises made to parents and children who provide their
samples and information. If they are not properly run, there is
a potential for harm and a lost opportunity to advance child-
ren’s health. Properly run pediatric biobanks entail responsibil-
ities for institutes, custodians, researchers, and research ethics
committees, as we have outlined here.
Areas for future research include identifying levels of risk in
collecting, using, storing and sharing samples in different types
of pediatric biobanks according to the type of research being
undertaken, and determining the implications for return of
individual results in the pediatric context.
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